Skip to main content

Table 4 Clinical responses to infliximab

From: Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease

Change from baselinea

Median (IQR)

p-valueb

 

Infliximab

Placebo

 

TNF-alpha high subset b

   

FEV1

0.0 (-4.0, 4.0)

-2.3 (-6.0, 1.0)

0.11

CRQ

8.0 (0.0, 21.5)

4.0 (-1.5, 19.0)

0.34

6MWD

0.0 (-39.0, 41.0)

21.2 (-49.4, 41.7)

0.93

Dyspnea

0.0 (0.0, 2.0)

0.0 (0.0, 2.8)

0.98

log2(CRP)

0.1 (-1.1, 0.9)

-0.7 (-1.5, 0.2)

0.10

CRP high subset c

   

FEV1

-1.8 (-4.0, 4.0)

-2.1 (-6.0, 2.0)

0.51

CRQ

17.0 (0.0, 28.5)

4.0 (0.0, 24.0)

0.38

6MWD

3.4 (-55.6, 66.0)

0.0 (-47.7, 35.0)

0.67

Dyspnea

0.0 (-3.0, 2.0)

0.0 (0.0, 2.0)

0.40

log2(CRP)

-1.1 (-1.9, -0.2)

-0.4 (-1.0, 0.4)

0.075

  1. aChanges from baseline in the indicated parameter in combined infliximab (3 mg/kg + 5 mg/kg) or placebo treatment, within the specified T54 COPD subpopulation.
  2. bMann-Whitney p-value for combined infliximab group vs placebo group within the indicated T54 COPD subpopulation.
  3. cTNF-alpha high subset = top quartile for baseline serum TNF-alpha levels (> 6.8 pg/ml).
  4. dCRP high subset = top quartile for baseline serum CRP levels (> 6.9 ug/ml).
  5. CRP, C-reactive protein; CRQ, chronic respiratory questionnaire; FEV1, forced expiratory volume in 1 second; IQR, interquartile range; MWD, minute walk distance; TNF-alpha, tumor necrosis factor-alpha.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us